Graciela B. Arhancet

Discovery of (3<i>S</i>,3a<i>R</i>)-2-(3-Chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2<i>H</i>-benzo[<i>g</i>]indazole-7-carboxylic Acid (PF-3882845), an Orally Efficacious Mineralocorticoid Receptor (MR) Antagonist for Hypertension and Nephropathy

Marvin J. Meyers, Graciela B. Arhancet, Susan L. Hockerman et al. · Journal of Medicinal Chemistry · 2010 · 91 citations · Full text

Excellent Potency, Exquisite Potency, Renal Inflammation +19

Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation

Graciela B. Arhancet, Daniel P. Walker, Sue Metz et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 48 citations · Full text

Inflammation, Bioavailable Mpges-1 Inhibitor, Anti-inflammatory +8

Discovery of Novel Cyanodihydropyridines as Potent Mineralocorticoid Receptor Antagonists

Graciela B. Arhancet, Scott S. Woodard, Kaliappan Iyanar et al. · Journal of Medicinal Chemistry · 2010 · 45 citations · Full text

Hypertension, Functional Selectivity, Medicine +9

Stereochemical Requirements for the Mineralocorticoid Receptor Antagonist Activity of Dihydropyridines

Graciela B. Arhancet, Scott S. Woodard, Jessica D. Dietz et al. · Journal of Medicinal Chemistry · 2010 · 38 citations · Full text

Pharmacotherapy, Chemical Biology, Pharmaceutical Chemistry +16

Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPAR gamma.

Charles W. Bolten, Patrick M. Blanner, William Graham McDonald et al. · PubMed · 2007 · 38 citations · Full text

Mitochondrial Binding Site, Pharmacotherapy, Experimental Pharmacology +16